Dendritic Cell Vaccine Therapy With In Situ Maturation in Pediatric Brain Tumors

Summary

DC vaccine manufactured and partially matured using our standard operating procedures, developed in collaboration with the HGG Immuno Group, then administered through imiquimod treated skin will be safe and feasible in children with refractory brain tumors. This will result in anti-tumor immunity that will prolong survival of subjects treated and results will be consistent with the outcomes found for subjects treated by HGG Immuno Group investigators. Study treatment will correlate with laboratory evidence of immune activation. Correlative studies will also reveal targets in the immune system which can be exploited to improve response for patients on successor trials.

Timeline

Start

2013-09-03

Primary completion

2016-10-24

Completion

2017-01-26

Drugs

Indications